# 0 1Narrow search Terms

**Page range:** 35–37

```text
0
1Narrow search Terms
*One patient experienced both Pneumonia cytomegaloviral and Pneumocystis jirovecii pneumonia
No patients incurred an opportunistic infection with Grade 5 severity.
MedDRA Version 27.0. SMQ: Standard MedDRA Query
Source: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
output/t_ae_OPPINF3_MAIN_SE_12JUL2024_42864.out
Table 8
Summary of Corticosteroid Use in Patients with Severe
Opportunistic Infections in AcceleRET-Lung
Patient ID
Opportunistic
Infection PT
Onset day/Duration
Corticosteroid Use
Prior to AE Onset
(Yes/No)
Corticosteroid Use
at onset or during
the opportunistic
infection (Yes/No)
Corticosteroid Details
3301/008
Pneumonia
cytomegaloviral
SD 85 – 105
No
Yes
(Onset and following
the infection)
Methylprednisolone IV
QD (SD 85 – 93)
Prednisolone PO QD
(SD 94 - 103)
3302/007
Pneumonia
cytomegaloviral
(SD 161 - ongoing)
Pneumocystis jirovecii
pneumonia (SD 161 -
193)
No
Yes
During only
Prednisolone PO QD
(SD 178 -186)
Methylprednisolone
sodium succinate IV
(SD 186 – 190 BID; SD
210-211 QD 212 – 217
BID, SD 218 – 220 QD,
SD 220 – 225 BID)
4410/008
Pneumonia legionella
SD 26 - 62
No
No
_
4517/001
Bronchopulmonary
aspergillosis
SD 148 - 208
Yes
Prior: Inhalational use
only
Yes
(During and following
the infection)
Beclometasone
dipropionate,
formoterol, fumarate
(SD: -143 – 208
inhalation QD)

36
Drug Safety Report No: 1132062
Patient ID
Opportunistic
Infection PT
Onset day/Duration
Corticosteroid Use
Prior to AE Onset
(Yes/No)
Corticosteroid Use
at onset or during
the opportunistic
infection (Yes/No)
Corticosteroid Details
Budesonide (SD: 46 –
49, inhalation PRN)
Budesonide (SD 147 –
150 inhalation BID)
Dexamethasone (SD
246 IV QD)
Prednisone (SD 247-
291 PO QD);
Budesonide (SD: 405-
436 Nasal BID);
Methylprednisolone
(SD: 405-406 IV TID);
Prednisone (SD: 406-
408 IV QD)
4801/002
Pneumocystis jirovecii
pneumonia
SD 55 - 75
Yes
Yes
(Following)
Fluticasone furoate,
vilanterol trifenatate
(SD: -68 - unk
inhalation QD);
Fluticasone furoate:
SD: -37 – unk nasal
PRN); Dexamethasone
(SD: -20 to Unk PO
QD; SD 64 – 72 IV
BID; SD 74 – 75 PO
QD)
7301/006
Oesophageal
candidiasis (SD 280 –
301)
Yes
Yes
(During)
Ciclesonide (SD: -39 –
376 inhalation QD)
Prednisone (SD: 153 –
162 PO QD)
Budesonide (SD 274 –
unk inhalation, BID)
8411/001
Pneumocystis jirovecii
pneumonia
SD 66 - 127
No
Yes
(Following)
methylprednisolone
sodium succinate (SD:
69 – 71 IV QD)
prednisolone (SD 72 –
88 IV QD)
Prednisolone (SD 89 –
127 PO QD)
SD: Study Day; QD: once daily, BID: Twice daily; TID: Thrice daily; PO: per oral, IV: Intravenous; PRN: As
needed; unk: Unknown
Source:
root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_cm_opp
inf_SE_12JUL2024_42864.out

37
Drug Safety Report No: 1132062
```